Distant relapse dominated early-stage p53-abnormal endometrioid disease
Early-stage endometrioid endometrial cancer with a p53-abnormal pattern behaved more aggressively than its stage label suggests. In a multicenter retrospective cohort from six hospitals in the Republic of Korea, 86 women with FIGO stage I–II disease were treated between 2013 and 2023, and recurrence was not confined to the pelvis. Of the 16 patients who relapsed, 12 had distant metastases, a pattern that immediately shifts the clinical concern away from local control alone and toward occult systemic spread at the time adjuvant therapy is chosen.
The progression-free survival estimates were 91% at 12 months, 78% at 24 months, and 76% at 36 months. Those numbers suggest that the first year after treatment may look reassuring, yet the curve continues to erode over time, consistent with disease that can escape local treatment and later declare itself at distant sites. For clinicians, that matters because radiation alone is designed to sterilize microscopic disease in the pelvis and vaginal cuff; it does not address circulating or already seeded tumor cells elsewhere in the body.
This study focused on a biologically defined subgroup rather than a broad early-stage endometrial cancer population. That distinction is important because p53-abnormality is generally associated with more aggressive behavior, and the data here reinforce that this molecular feature can override the comfort that often comes with early stage disease. In practical terms, a small, early-stage tumor with an adverse molecular profile may carry a recurrence risk that looks closer to high-risk systemic disease than to low-risk uterine-confined cancer.
Chemotherapy trended ahead of radiation-based adjuvant treatment
Adjuvant chemotherapy showed a trend toward improved progression-free survival compared with adjuvant radiation therapy with or without chemotherapy, with a p value of 0.10. The finding does not establish superiority, but it does align with the relapse pattern observed in the cohort. If most failures are distant, a systemic approach has a biologic advantage over a treatment plan centered on local field control.
The study’s multivariable analysis sharpened the risk signal further. Among the p53-abnormal subtypes, the p53-overexpression pattern was independently associated with worse progression-free survival than the p53-null pattern, with a hazard ratio of 8.59, a 95% confidence interval of 1.61 to 45.79, and p=0.01. The size of that effect is striking, even though the wide confidence interval reflects the modest sample size and the uncertainty that comes with a retrospective dataset. One subgroup carried a much steeper hazard than the other, and the separation was large enough to persist after adjustment.
The biologic logic is straightforward. Abnormal p53 signaling reflects disruption of a central tumor-suppressor pathway that normally helps restrain genomic damage and malignant progression. When that control is lost, tumors may accumulate additional genomic instability and gain metastatic capability, which would fit the distant recurrence profile seen here. Radiation can still matter for local disease control, but once the dominant failure mode becomes systemic dissemination, chemotherapy becomes the more plausible backbone for adjuvant therapy.
This is the kind of cohort in which molecular classification starts to shape bedside decisions in a more concrete way. Early-stage designation alone may no longer be sufficient to justify a purely locoregional adjuvant strategy when the recurrence pattern points outward rather than inward.
What the recurrence pattern means for postoperative decision-making
The study supports a cautious reappraisal of adjuvant treatment choices in women with endometrioid early-stage endometrial cancer and a p53-abnormal pattern. A recurrence rate that is driven largely by distant metastasis argues for systemic therapy consideration even when anatomic staging appears favorable. The observed trend toward better progression-free survival with chemotherapy, combined with the independent adverse prognostic impact of p53-overexpression, points toward chemotherapy as a reasonable option to discuss in this subgroup.
The findings also raise a more granular question about whether all p53-abnormal tumors should be treated the same way. The difference between p53-overexpression and p53-null patterns was not subtle in this dataset. If those subtypes continue to separate in larger cohorts, postoperative risk stratification may need to move beyond a single binary label and into more detailed molecular subclassification.
The retrospective design places clear boundaries around interpretation. Treatment selection was not randomized, so any apparent advantage for chemotherapy could reflect clinical selection factors, pathology features, or other unmeasured differences between groups. The cohort also remained relatively small, which widens the confidence interval around the hazard estimate and limits the precision of subgroup comparisons. Even so, the recurrence geography is hard to ignore: distant relapse was the dominant pattern, and that pattern is difficult to reconcile with an adjuvant strategy centered mainly on local radiation.
For now, the most defensible clinical reading is narrow and specific. In women with stage I–II endometrioid endometrial cancer and p53-abnormality, postoperative planning should account for systemic relapse risk, not just pelvic control. Chemotherapy may deserve stronger consideration than radiation alone in this setting, while the prognostic separation between p53-overexpression and p53-null disease needs confirmation in larger prospective studies with treatment strategies assigned more rigorously than they can be in a retrospective review.